--> Watch GSK, AZN...
Pfizer May Pursue Innovative Business or Inversion Deal:JPMorgan
2015-05-28 12:23:07.435 GMT
By Cristin Flanagan and Joshua Fineman
(Bloomberg) -- Pfizer could pursue new deal in S-T as it
seeks to strengthen its innovative business, JP Morgan analyst
Chris Schott writes, notes BMRN, MDVN, Shire, Swedish Orphan,
VRTX as possible branded asset targets.
* May target commercial stage assets with anticipated ramp up
in next 5-10 years; can’t “rule out” inversion deal
* Sees limited possible inversion candidates, lists ACT, AZN,
Bayer
* Sees possible catalysts ahead of potential break-up in 2017
* SOTP analysis implies upside to $40/shr
* NOTE: May 22, All Eyes on Pfizer as Shareholders Await the
Mega-Deal: Real M&A
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporters on this story:
Cristin Flanagan in New York at +1-212-617-8919 or
cflanagan1@bloomberg.net;
Joshua Fineman in New York at +1-212-617-8953 or
jfineman@bloomberg.net
To contact the editors responsible for this story:
Arie Shapira at +1-212-617-1488 or
ashapira3@bloomberg.net
Cristin Flanagan
2015-05-28 12:23:07.435 GMT
By Cristin Flanagan and Joshua Fineman
(Bloomberg) -- Pfizer could pursue new deal in S-T as it
seeks to strengthen its innovative business, JP Morgan analyst
Chris Schott writes, notes BMRN, MDVN, Shire, Swedish Orphan,
VRTX as possible branded asset targets.
* May target commercial stage assets with anticipated ramp up
in next 5-10 years; can’t “rule out” inversion deal
* Sees limited possible inversion candidates, lists ACT, AZN,
Bayer
* Sees possible catalysts ahead of potential break-up in 2017
* SOTP analysis implies upside to $40/shr
* NOTE: May 22, All Eyes on Pfizer as Shareholders Await the
Mega-Deal: Real M&A
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporters on this story:
Cristin Flanagan in New York at +1-212-617-8919 or
cflanagan1@bloomberg.net;
Joshua Fineman in New York at +1-212-617-8953 or
jfineman@bloomberg.net
To contact the editors responsible for this story:
Arie Shapira at +1-212-617-1488 or
ashapira3@bloomberg.net
Cristin Flanagan